Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Vaccines that protect against infectious diseases like the flu or pneumonia are commonly made from a weakened form of the ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

As cervical cancer awareness month concludes, health officials stress the importance of regular screenings and the HPV ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

Personalised vaccines will be tested on children with untreatable brain tumours as part of a world-first clinical trial ...